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Long-term results of infrainguinal bypass grafts
for limb-threatening ischemia in the absence of
autologous saphenous vein are poor. New graft
materials and techniques have been used in an
attempt to improve the results.1-6 However, report-
ed patency and limb salvage rates are still lower than
those obtained with autologous saphenous vein.
Arterial allografts (AAs) were widely used in the
1950s.7 They were soon abandoned for prosthetic
grafts because of low patency rates and frequent
aneurysmal degeneration.8,9 Since then, tissue
preservation techniques have improved, with new
preservation media and cryopreservation being now
available. For these reasons, AAs were recently
reconsidered in two indications: prosthetic graft
infection10 and limb salvage. Previous reports on the
results of AA bypass grafts for critical ischemia stud-
ied small groups of patients with a short-term fol-
low-up.11-13 The aim of this study was to assess
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Purpose: Arterial allografts (AAs) have been recently reconsidered in the treatment of
critical limb ischemia when vein material is absent, because of the disappointing results
with artificial grafts. The aim of this study was to report the results observed in three
centers where AAs were used for infrainguinal reconstruction in limb-threatening
ischemia.
Methods: Between 1991 and 1997, 165 AA bypass procedures were performed in 148
patients (male, 90) with a mean age of 70 years (range, 20-93 years). Indications for
operation were rest pain in 54 cases and tissue loss in 111 cases. Mean resting ankle pres-
sure was 53 mm Hg in 96 patients who did not have diabetes and mean transcutaneous
pressure of oxygen was 10 mm Hg in 52 patients who did have diabetes. In 123 cases
(75%), there was at least one previous revascularization on the same limb. AAs were
obtained from cadaveric donors. The distal anastomosis was to the below-knee popliteal
artery in 34 cases, to a tibial artery in 114 cases, and to a pedal artery in 17 cases. 
Results: At 30 days, the mortality rate was 3.4%; the primary patency rate was 83.3%; the
secondary patency rate was 90%; and the limb salvage rate was 98%. During follow-up
(mean, 31 months), 65 grafts failed primarily. Causes of primary failure were thought
to be progression of the distal disease in 15 cases, myointimal hyperplasia in 16 cases,
graft degradation in 10 cases (four dilations, three stenoses, two ruptures, and one dis-
section), miscellaneous in eight cases, and not known in 16 cases. Primary patency rates
at 1, 3, and 5 years were, respectively, 48.7% ± 4%, 34.9% ± 6%, and 16.1% ± 7%.
Secondary patency rates at 1, 3, and 5 years were, respectively, 59.8% ± 4%, 42.1% ± 5%,
and 25.9% ± 8%. Limb salvage rates at 1, 3, and 5 years were, respectively, 83.8% ± 3%,
76.4% ± 5%, and 74.2 % ± 8%. 
Conclusion: AA leads to an acceptable limb salvage rate but poor patency rates. A ran-
domized trial that will compare AAs and polytetrafluoroethylene should be undertaken.
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long-term results of AAs in patients with limb-
threatening ischemia.
METHODS
Patients. Between April 1991 and June 1997,
148 patients from three centers underwent 165 AA
bypass grafts. Patient distribution among the three
centers (A, B, and C) was, respectively, 73, 46, and
29 patients. There were 90 male patients and 58
female patients. The mean age was 70 years (range,
20-93 years). The risk factors and major comorbidi-
ties are shown in Table I. The indications for opera-
tion were rest pain in 54 cases, minor tissue loss in 94
cases, and major tissue loss in 17 cases. Patients with
acute ischemia were excluded from the study. Mean
resting ankle pressure was 53 mm Hg (range, 0-140
mm Hg) in patients who did not have diabetes.
Patients with diabetes had a mean transcutaneous
oxygen pressure of 10 mm Hg (range, 0-30 mm
Hg). All patients underwent preoperative angiogra-
phy. Run-off scores were calculated as recommended
by the Ad Hoc committee on Reporting Standards.14
The mean score was 5.5 (range, 1-10). For 45 revas-
cularizations (27%), the score was equal or greater
than 8. In 123 cases (75%), there was at least one
previous revascularization on the same limb and, in
41 cases (25%), at least two previous revasculariza-
tions. AA was indicated in 127 cases because of the
absence of greater saphenous vein and in 38 cases
because of its unsuitability (dilation, small size, calci-
fications). ABO matching was not achieved in 21
cases because no matching graft was available. The
surgeon felt that the potential benefit for the patient
was greater than the risk of having a complication
from an ABO mismatch. The site of the distal and
proximal anastomosis are shown in Table II. Thirty-
one bypass grafts were composite. In 14 cases a com-
bination graft with polytetrafluoroethylene (PTFE)
for the proximal anastomosis was used because the
AA was too short. In 16 cases a combination with a
piece of saphenous vein for the distal anastomosis was
used because of the caliber discrepancy between the
AA and a small tibial vessel. A combination graft with
both PTFE and saphenous vein was used in one case.
Seventeen bypass grafts were sequential. The inter-
mediate patent segment was the popliteal artery in
eight cases, the superficial femoral artery in two
cases, the deep femoral artery in two cases, and a tib-
ial artery in five cases. There were 153 first AA bypass
grafts and 12 second AA bypass grafts, the latter
being performed because of failure of previous AA
bypass graft. Intravenous heparin was administered
the first days after operation. Patients were eventual-
ly given antiplatelet drugs in 41 cases, oral anticoag-
ulants in 37 cases, and antiplatelet drugs plus oral
anticoagulants in 87 cases. 
Arterial allografts processing. AAs were har-
vested from brain-dead donors as part of the multi-
ple-organ harvesting program. Donors were
screened for hepatitis B and C virus, human
immunodeficiency virus, and cytomegalovirus. If
one of the tests was positive, the patient did not
undergo harvesting. Surgical, atraumatic harvesting
involved descending thoracic aorta and arteries of
the limbs from the aortic bifurcation to the tibioper-
oneal trunk. Then, AAs were placed in sterile preser-
vation medium with added antibiotics and fungi-
cides. Fresh allografts (n = 45) were used at the
beginning of this experience when cryopreservation
techniques had not been applied to AAs. They were
kept sterile at 4°C in the initial medium until the
revascularization was performed. The mean delay
between harvesting and grafting was 14 days; the
maximum delay was 40 days.
Cryopreserved AAs were processed within 48
hours after harvest. Before that, samples for bacteri-
ologic analysis were collected from the initial preser-
vation medium. AAs were put in freezing bags
Table I. Risk factors and major comorbidities
N %
Risk factor
Tobacco use 46 31
Diabetes 52 35
Hypertension 96 65
Hyperlipidemia 20 13
Comorbidity
Cardiac disease 59 40
Renal failure 26 18
Table II. Site of proximal and distal anastomosis
Site N
Proximal anastomosis
Iliac artery 16
Common femoral artery 106
Superficial femoral artery 38
Above-knee popliteal artery 1
Below-knee popliteal artery 4
Distal anastomosis
Below-knee popliteal artery 34
Tibioperoneal trunk 10
Anterior tibial artery 40
Posterior tibial artery 25
Peroneal artery 39
Pedal artery 17
(Hemofreeze bag; NBPI, Emmer-compascuum, The
Netherlands), and dimethyl sulfoxide was added.
AAs were then frozen progressively in a Digitcool
device (Cryo Bio System, L’aigle, France), with a
programmed decreasing rate in temperature. They
were stored in nitrogen vapor between –120°C and
–150°C. The composition of initial preservation
medium and cryopreservation protocol used in the
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three centers are summarized in Table III. AAs were
discarded in the case of positive bacterial culture. For
cryopreserved AAs, a minimal delay of 4 months was
allowed before the graft was used. Thus it was possi-
ble to look for seroconversion in recipients of the
organs harvested from the same donor. If serocon-
version was found, corresponding AAs were discard-
ed. When the use of an AA for a patient was decided,
the freezing bag was placed in a water bath at 37°C
to thaw. AAs were not manipulated until totally
thawed to avoid fractures. A new sample for bacteri-
al analysis was performed once the bag was opened.
Collateral branches of the graft were ligated with 6-
0 polypropylene sutures. The standard infrainguinal
bypass grafting procedure was performed. 
Follow-up. At the beginning of the study period,
an invasive follow-up was performed in the center
that started this technique. At 3 months, angiography
(Fig 1) and biopsy under local anesthesia were per-
formed to detect rejection or morphologic changes of
the allograft. In the other two centers, duplex scan
was performed after the operation at 3, 6, and 12
months and yearly thereafter. When the graft was
patent, anomalies seen either on duplex scan or
angiography were considered to be a failure only if
they required an intervention. Primary patency curves
were established, with those failures considered occlu-
sions. Anomaly of the allograft was defined as follows:
stenosis of proximal or distal anastomosis, graft dila-
tion, graft rupture, mid-graft stenosis (as opposed to
anastomotic stenosis), graft dissection, or adherent
thrombus. Graft degradation was defined as an alter-
ation of the structure of the graft (excluding the anas-
tomosis) that occurred during follow-up and includ-
ed dilation, rupture, stenosis, and dissection. For dila-
tions and stenoses, the following criteria assessed by
duplex scan and/or angiography prompted revision
of the graft: dilation greater than 50% of the artery
diameter immediately above the dilated segment;
stenosis of 60% to 70% or greater. 
Statistical analysis. Cumulative primary and
secondary patency, limb salvage, and survival rates
were assessed with the use of the life-table method.
Comparison of estimates was performed with the
log-rank test.
RESULTS
Postoperative results. Five patients (3.4%) died
during the 30-day postoperative period: two patients
had myocardial infarction, and one patient had stroke.
One patient had preoperative anemia as the result of
renal failure. She had a long procedure that resulted
in significant worsening of the anemia and subse-
Fig 1. Completion angiogram of a femoroposterior tibial
AA bypass grafting.
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quently experienced cardiac failure. The cause of
death was not known for the last patient, aged 88
years, who had poor general condition and who died
after an above-knee amputation. None of these deaths
were related to a specific complication of the AA.
Thirty grafts failed after the operation. Twenty-eight
grafts occluded; one patient had worsening tissue loss
despite graft patency, and one patient had a thrombus
(seen on postoperative duplex scan) that required
subsequent revision. Causes for occlusion were
thought to be poor run-off in 16 cases, technical
error in 3 cases, graft stenosis in 1 case, low-flow state
in 1 case, sudden interruption of anticoagulant treat-
ment in 1 case, and unknown in 6 cases. The patient
underwent surgical revision in 14 cases and a redo
procedure in one case (ie, the allograft was removed,
and a new AA bypass grafting was performed); the 13
remaining patients had no further procedure.
Amputation was required in five cases. Primary and
secondary patency and limb salvage rates at 1 month
were 83.3%, 90%, and 98%, respectively. 
Late results. Mean follow-up was 31 months
(range, 1-81 months). Sixty-one patients died dur-
ing follow-up. Long-term survival rates are shown in
Fig 2. In 12 cases (7.3%), a complete surveillance
program could not be achieved, and patients were
considered lost to follow-up for patency at the date
of their last duplex scan. We observed 65 primary
failures (48%): 56 occlusions, 5 stenoses of the distal
anastomosis, 1 stenosis of the graft, 2 dilations, and
1 rupture. Causes of primary failure are reported in
Table IV. One patient who had a ruptured allograft
subsequently died of hemorrhage before surgery
could be attempted. Among patients from the “mis-
cellaneous” group, two patients had sudden inter-
ruption of anticoagulant treatment; one patient had
constitutional deficit in S protein; one patient expe-
rienced the development of stenosis of the external
iliac artery, which was dilated; and one patient had
open ankle dislocation (this patient experienced the
development of extensive necrosis of the wound,
and the limb had to be amputated although the
bypass graft was patent). Finally, 15% of late prima-
ry failures (10/65 failures) were due to graft degra-
dation, whereas 48% of late primary failures (31/65
failures) were due to either progression of distal dis-
ease or myointimal hyperplasia.
Forty-one grafts had further procedures after pri-
mary failure. Thirty-five grafts were surgically revised,
and two grafts had thrombolysis. In four cases, a new
AA bypass graft was performed. Twenty-four grafts
had no further procedure after primary failure. After
secondary procedure, 23 grafts occluded again, five of
which were replaced by a new allograft. Major ampu-
tation was required for 25 limbs. Another six grafts
had moderate dilations (ie, less than 50% of the diam-
eter of the graft above the dilation), and two grafts
had moderate stenosis of the distal anastomosis (less
than 60%). They did not require an intervention and
Table III. Composition of the initial preservation medium and cryopreservation protocol in the three centers
Center A Center B Center C
Initial preservation medium Eurocollins17 Belzer16 RPMI 164015
Gentamicin 240 mg/L Gentamicin 240 mg/L Gentamicin 20 mg/L
Colistin 105 U/L Colistin 106 U/L Metronidazole 500 mg/L
Lincomycine 100 mg/L Lincomycine 400 mg/L Cefuroxime 750 mg/L
Amphotericin B 50 mg/L
Hepes 5 10-4 mol/L
Heparin 7500 U/L
20% Human albumin 2.5 mL
Cryopreservation protocol
Storage temperature (°C) –120 –150 –160
DMSO concentration (%) 15 15 10
DMSO, Dimethyl sulfoxide.
Table IV. Causes of late primary failures 
Cause N
Myointimal hyperplasia 16
Progression of distal disease 15
Graft degradations
Aneurysm 4
Stenosis 3
Rupture 2
Dissection 1
Miscellaneous
Anticoagulation 3
Low flow states 2
External compression 1
Inflow disease 1
Limb injury 1
Unknown 16
TOTAL 65
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were followed up. No adverse event as the result of
the systematic sampling was observed. 
Primary patency rates at 1, 3, and 5 years were
48.7% ± 4%, 34.9% ± 6%, and 16.1% ± 7% (Fig 3).
Secondary patency rates at 1, 3, and 5 years were
59.8% ± 4%, 42.1% ± 5%, and 25.9% ± 8% (Fig 3).
Limb salvage rates at 1, 3, and 5 years were 83.8% ±
3%, 76.4% ± 5%, and 74.2 ± 8% (Fig 4). Comparisons
of patency rate according to secondary variables are
shown in Table V. Primary and secondary patency
Fig 2. Life-table analysis for survival. The figure above each plot point indicates the number
of patients at risk at the beginning of the interval. The figure on the right (44 ± 6) indicates
the cumulative survival at 5 years ± SE.
Fig 3. Life-table analysis for primary and secondary patency. The figure above each plot point
indicates the number of grafts at risk at the beginning of the interval. The figures on the right
indicate cumulative primary and secondary patency at 5 years ± SE.
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rates of below-knee and infrapopliteal AA are shown
in Fig 5.
Pathologic examination. Fourteen pathology
reports of AA samples (obtained 3 months or more
after implantation) were available for analysis. In five
cases systematic biopsies were performed at 6 months.
Four AAs were explanted because of graft degrada-
tion (three dilations and one dissection). The remain-
ing five samples were obtained during secondary pro-
cedures for graft occlusion. Lymphomonocytic infil-
tration was found in five cases. From these five AAs,
only one had graft degradation (ie, dissection). In
most of cases, endothelial and smooth muscle cells
were absent, with marked medial fibrosis.
DISCUSSION
The allograft degradation rate leading to primary
failure in this study was about 3%. This is lower than
reported earlier.8,9 Several reasons might explain this
difference. New preservation media15-17 may cause
less damage to AAs than the ones used in the 1950s.
Use of cryoprotectant solution and controlled freez-
Fig 4. Life-table analysis for limb salvage in the whole series. The figure above each plot point
indicates the number of limbs at risk at the beginning of the interval. The figure on the right
indicates the cumulative limb salvage at 5 years ± SE. 
Table V. Comparison of patency rates according to secondary variables with the log-rank test
Secondary variable Log-rank value P value
ABO matching (yes vs no) 0.265 >.05
Preservation (fresh vs cryopreservation) 0.265 >.05
Center (A vs B) 0.088 >.05
Center (B vs C) 0.087 >.05
Center (C vs A) 0.238 >.05
Previous interventions (none vs one or more) 0.340 >.05
Site of distal anastomosis (below-knee vs infrapopliteal) 0.885 >.05
Run-off score (<5 vs ≥5) 0.808 >.05
Composite (yes vs no) 0.145 >.05
Sequential (yes vs no) 0.095 >.05
Anticoagulant protocol (AP vs OA) 0.028 >.05
Anticoagulant protocol (AP vs OA+AP) 0.521 >.05
Anticoagulant protocol (OA vs OA+AP) 0.398 >.05
Secondary intervention (yes vs no) 0.524 >.05
AP, Antiplatelet therapy; OA, oral anticoagulant.
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ing rate are important improvements that prevent cell
damage during freezing. Bench test studies have
shown preservation of mechanical properties after
cryopreservation.18,19 Several studies have shown the
preservation of endothelial and smooth muscle cells
properties (contractile activity, endothelium-depen-
dent and independent relaxation) of AAs after cryo-
preservation.20,21 The incidence of graft rupture was
1.2% (2/165 grafts), which suggests that this condi-
tion is unusual. However, one of the two patients
died of this complication. This is a severe condition;
and if more of these should arise in the future, the
technique should certainly be abandoned. Graft dila-
tion did not cause death to our knowledge but was
responsible for redo procedures. These shortcomings
do not exist with prosthetic grafts. However, infec-
Fig 5. Separate life-table analysis for primary and secondary patency of below-knee (BK) and
infrapopliteal bypass grafts. The figures (bold type) in the table are cumulative patency rates ±
SE, and the figures in parentheses indicate the number of grafts at risk at the beginning of the
interval.
Table VI. Primary patency of infrapopliteal PTFE bypass grafts without adjunctive procedures
Primary patency (%)
Study Year 1 yr 2 yr 3 yr 4 yr 5 yr
Fichelle et al29 1995 61 48 43 42 —
Parsons et al30 1996 71 47 39 36 28 
Schweiger et al31 1993 51 46 37 31 —
Davies et al32 1991 37 33 31 25 22
Veith et al33 1986 46 34 30 12 —
Rafferty et al34 1987 31 21 19 17 14
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tion of a prosthetic graft can lead to dramatic compli-
cations, in which severity may be similar to arterial
allograft rupture. Indeed, incidence of femoro-distal
bypass graft infection can be up to 3%, with mortality
rates up to 27%.22 There was no case of graft infection
in this series, and clinical and experimental data10,23,24
show that AAs are more resistant to infection than
prosthetic grafts. Whether the incidence of severe
graft complications is lower when a PTFE graft is
used in this population of patients still has to be
proved.
There have been some controversies about what
type of preservation (ie, fresh or cryopreservation)
should be used. The important advantage of cryo-
preserved AA is a better protection against infection
transmission. Longer storage periods allow a time
interval for viral screening of other recipients and, if
positive, to discard corresponding AA. For this rea-
son, we think it is no longer ethical to use fresh allo-
grafts. The problem of protection against prions is a
real concern and is not solved yet because of very
limited knowledge of the disease.
It is likely that immunologic rejection of AA
exists. Pathologic examination of explanted AAs in
this study favor this hypothesis: lymphocyte infil-
tration of the media and the adventitia have been
found. Absence of endothelium and fibrosis of the
media were the most common pathologic features.
They are similar to those shown in experimental
rat models of AA immunologic rejection.25,26
However, we do not know the incidence and the
clinical significance (ie, graft degradation and graft
occlusion) of the rejection phenomenon. No dif-
ference was found when patency rates were com-
pared according to ABO matching (Table V).
There was no graft degradation in the non-
matched ABO group. These data suggest that ABO
matching does not play an important role in the
maintenance of patency and avoidance of degrada-
tion. Encouraging results have been obtained with
AAs in patients who receive immunosuppressive
treatment after kidney transplantation,12 but this
series included only 13 patients with short-term
follow-up. Patients were not given immunosup-
pressive drugs in this study for the following rea-
sons: toxicity of available drugs (especially renal
toxicity with cyclosporin) would not be tolerated in
older patients with poor general condition; risk of
infection in patients with tissue loss would be high;
in randomized trials, immunosuppressive drugs
have failed to improve patency and limb salvage
rates with cryopreserved venous allografts27; and
the cost/benefit ratio was likely to be high for
patients with low life expectancy.
Although postoperative patency rates were
good, late patency rates were poor. Good early
results can be explained by the fact that AAs are
easy to handle. Indeed, elastic properties close to
those of a normal artery and caliber consistency
with small tibial arteries facilitated the realization of
the distal anastomosis. Forty-eight percent of late
primary failures were due to either progression of
distal disease or myointimal hyperplasia, whereas
only 15% were due to graft degradation. The pro-
gression of distal disease and myointimal hyperpla-
sia have been described to be the main causes of
failure of PTFE grafts.28 These data suggest that
the potential advantage of AAs over PTFE grafts
would be to decrease the incidence of early failure
caused by technical problems. In the long-term,
AAs seem to behave the same as PTFE grafts,
because their causes of failure are similar.
Table VII. Primary patency of infrapopliteal PTFE bypass grafts plus adjunctive procedures (cuff, patch,
arteriovenous [A-V] fistulas)
Type of
Primary patency (%)
adjunctive procedure Study Year 1 yr 2 yr 3 yr 4 yr 5 yr
Cuff ± A-V fistula Wijesinghe et al35 1998 64 51 — — —
Morris et al36* 1993 29 29 27 23 —
Morris et al36† 1993 25 20 17 14 —
Harris et al37 1993 61 61 — — —
A-V fistula Ascer et al1‡ 1996 78 70 61 — —
Patch Taylor et al4 1992 74 — 58 — 54
Fichelle et al29 1995 — — 45 — — 
*Primary procedures.
†Secondary procedures.
‡Assisted primary patency.
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There was an important discrepancy between
poor late patency and acceptable limb salvage rates.
At least two explanations can be given. Some
patients may have healed, or rest pain would have
settled without operation. It is difficult to predict
which patients will have this spontaneous favorable
outcome, on clinical grounds and with the noninva-
sive techniques currently available. Collateral circu-
lation, which developed although the bypass graft
was patent, might have provided sufficient blood
supply to avoid the recurrence of symptoms when
the bypass graft occluded. 
A number of secondary variables concerned the
different practices that existed in each center (ie,
preservation protocol, postoperative anticoagulant
treatment, follow-up protocol) and the different
types of grafts (ie, composite, sequential). Because
this was a retrospective study, there was no stan-
dardization of the methods between centers.
However, a comparison of patency rates according
to these variables was not significant (Table V),
which suggests that there may be other determinants
for patency and degradation. 
Patency rates obtained with AA were clearly worse
than those obtained with autologous saphenous vein.
But the comparison was not as easy with prosthetic
grafts. Table VI and VII show primary patency rates
of infrapopliteal bypass grafts for limb salvage
obtained with PTFE grafts alone or with adjunctive
procedures. The range of reported patency rates was
considerably wide. For example, primary patency
rates at 3 years varied from 17% to 61%. The primary
patency rate at 3 years obtained with infrapopliteal AA
bypass grafts was 31%. Clearly, reported patency rates
for PTFE grafts were either worse, equal, or better
than patency rates of AAs in this study. Furthermore,
the discrepancy between reported patencies may be
explained by differences other than the surgical tech-
nique itself, such as risk factors, comorbidities, and
severity of the disease. Because the patients in this
study had very advanced disease (with high run-off
scores and high incidence of comorbidities) and most
of them had several procedures before the allograft,
the results achieved with PTFE grafts might have
been worse. The answer to that question is critical
because better results would justify further use of AAs
for these patients. The solution of the problem is not
given by these data; only a randomized trial would
allow a comparison of the performance of AAs and
prosthetic grafts. It would also allow a comparison of
the incidence of graft-related complications in the
two techniques.
CONCLUSION
This study shows that AA infrainguinal bypass
grafts for critical ischemia leads to acceptable limb sal-
vage but poor patency rates. A randomized trial
would allow accurate comparison between AAs and
PTFE grafts. Only better results would justify further
clinical use of AAs. It seems possible to decrease the
incidence of degradations by an improvement of har-
vesting and preservation techniques and in our under-
standing of host-graft interactions. Experimental
investigations on that subject are to be continued.
We thank Mrs S. Acquart for her help in patient data
collection.
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